Edwards Lifesciences Corporation (NYSE:EW) Given Consensus Recommendation of “Moderate Buy” by Analysts

Edwards Lifesciences Corporation (NYSE:EW) has been assigned an average recommendation of “Moderate Buy” from the twenty-nine ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation, sixteen have assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $96.4545.

A number of research analysts have recently weighed in on the company. Truist Financial set a $92.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, December 5th. Wall Street Zen lowered Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 29th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $90.00 price target on shares of Edwards Lifesciences in a report on Monday, November 3rd. Citigroup reissued a “buy” rating and set a $101.00 price target (up from $96.00) on shares of Edwards Lifesciences in a research report on Thursday, December 11th. Finally, TD Cowen raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their price objective for the company from $90.00 to $97.00 in a report on Friday, January 9th.

Edwards Lifesciences Trading Down 0.1%

NYSE EW opened at $84.39 on Monday. Edwards Lifesciences has a 12-month low of $65.94 and a 12-month high of $87.89. The company has a fifty day simple moving average of $85.12 and a two-hundred day simple moving average of $80.59. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. The stock has a market cap of $48.97 billion, a P/E ratio of 36.38, a P/E/G ratio of 3.39 and a beta of 0.95.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The business’s quarterly revenue was up 14.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, analysts forecast that Edwards Lifesciences will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 11,340 shares of the business’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total value of $971,384.40. Following the completion of the transaction, the vice president owned 31,870 shares of the company’s stock, valued at $2,729,984.20. The trade was a 26.24% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at $1,885,571.40. The trade was a 4.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 57,824 shares of company stock valued at $4,863,323. 1.29% of the stock is owned by insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Several hedge funds have recently modified their holdings of the company. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences in the 3rd quarter worth about $25,000. Rosenberg Matthew Hamilton purchased a new stake in shares of Edwards Lifesciences in the second quarter valued at approximately $28,000. True Wealth Design LLC raised its stake in shares of Edwards Lifesciences by 251.5% during the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after buying an additional 259 shares during the period. NewSquare Capital LLC lifted its position in shares of Edwards Lifesciences by 57.8% during the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after buying an additional 134 shares in the last quarter. Finally, Hantz Financial Services Inc. grew its stake in Edwards Lifesciences by 76.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 164 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.